PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 28, 2026New England Journal of Medicine8 citations

Transdermal Estradiol Patches in Locally Advanced Prostate Cancer

View Full Paper
RLR. LangleyDGDuncan C. GilbertSMStephen Mangar

Key Points

  • The aim is to evaluate transdermal estradiol patches against LHRH agonists in metastasis-free survival for prostate cancer patients.
  • Analyzed efficacy of transdermal estradiol (tE2) in comparison to LHRH agonists over three years.
  • Monitored incidence of adverse effects like hot flashes and gynecomastia.
  • Involved patients with locally advanced prostate cancer.
  • Transdermal estradiol was noninferior to LHRH agonists for 3-year metastasis-free survival.
  • Hot flashes were less common in patients using estradiol patches.
  • Gynecomastia occurred more frequently among those treated with estradiol.

Abstract

In patients with locally advanced prostate cancer, tE2 was noninferior to LHRH agonists for 3-year metastasis-free survival, with a lower incidence of hot flashes but a higher incidence of gynecomastia. (Funded by Cancer Research U.K. and the U.K. Research Institute Medical Research Council; PATCH ClinicalTrials.gov number, NCT00303784; STAMPEDE-1 ClinicalTrials.gov number, NCT00268476.).

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Langley et al. (2026) studied this question.

synapsesocial.com/papers/69c770418bbfbc51511e076chttps://doi.org/10.1056/nejmoa2511781
Ask AI
Helpful
Bookmark
Share
View Full Paper